PPP1R13B and acute myeloid leukemia: To evaluate, if methylation of the PPP1R13B gene promoter is a target of and can be reversed by hypomethylating agents (HMA), MOLM-14 cells and patient derived freshly-isolated AML samples were treated with the DNA methyltransferase inhibitor decitabine.